FrancophonIA/ELRC3.0 huggingface dataset:
English: The Marketing Authorisation Holder provided supplementary information on 23 July 2007.
Estonian: Müügiloa hoidja esitas täiendava teabe 23. juulil 2007.
English: Ref. EMEA/CHMP/494914/2008
Estonian: London, 3. september 2008 Viide: EMEA/CHMP/494921/2008
English: Cozaar Comp and associated names, 50/12.5 mg; 100/12.5 mg; 100/25 mg, film coated tablets is a fixed dose combination of losartan and hydrochlorothiazide.
Estonian: Cozaar Comp ja sarnased nimetused (50/12,5 mg, 100/12,5 mg ja 100/25 mg) on losartaani ja hüdroklorotiasiidi fikseeritud annuse kombinatsiooni sisaldavad õhukese polümeerikattega tabletid.
English: Losartan is an orally active angiotensin II (Ang- II) receptor antagonist acting on the AT1 receptor subtype, thus blocking the effect of Ang-II in the renin angiotensin system (RAS) cascade.
Estonian: Losartaan on suu kaudu toimiv angiotensiin-II (Ang-II) retseptori antagonist, mis toimib retseptori AT1 alatüübile, blokeerides seega reniini-angiotensiini süsteemi (RAS) kaskaadis Ang-II toime.
English: The basis for referral was that there were divergences in the Summaries of Product Characteristics (SPC) of Cozaar Comp. and associated names approved across EU Member States, with respect to the following indications: Treatment of hypertension in patients whose blood pressure is not adequately controlled on losartan or hydrochlorothiazide; As first step treatment in patients with moderate to severe hypertension and in patients with high or very high cardiovascular risk; Reduction of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy.
Estonian: Esildise aluseks olid ravimi Cozaar Comp ja sarnaste nimetuste Euroopa Liidu liikmesriikides heakskiidetud ravimi omaduste kokkuvõtete erinevused seoses järgmiste näidustustega: hüpertensiooni ravi patsientidel, kellel ainult losartaani või hüdroklorotiasiidiga ei ole saavutatud küllaldast vererõhu langust; mõõduka kuni raske hüpertensiooniga patsientide ja suure või väga suure südameveresoonkonna riskiga patsientide esmavaliku ravi; südameveresoonkonna haigestumise ja suremuse vähendamine hüpertensiooniga patsientidel, kellel on vasaku vatsakese hüpertroofia.
English: Hydrochlorothiazide (HCTZ) is a thiazide diuretic which has also been used as an antihypertensive agent.
Estonian: Hüdroklorotiasiid on tiasiid-diureetikum, mida kasutatakse ka antihüpertensiivse ravimina.
English: During its 21 - 24 April 2008 meeting, the CHMP, in the light of the overall submitted data and the scientific discussion within the Committee, was of the opinion that the proposal for the harmonisation of the SPC, Labelling and Package leaflet was acceptable and that they should be amended.
Estonian: 21.-24. aprilli 2008 koosolekul oli inimravimikomitee, võttes arvesse esitatud kokkuvõtlikke andmeid ja komiteesisest teaduslikku arutelu, arvamusel, et ravimi omaduste kokkuvõtete, märgistuse ja pakendi infolehtede ühtlustamise ettepanek on vastuvõetav ning need dokumendid tuleb muuta.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II together with the amended SPC, labelling and package leaflet in Annex III.
Estonian: Asjaomased raviminimetused on esitatud I lisas, teaduslikud järeldused II lisas ning muudetud ravimi omaduste kokkuvõte, märgistus ja pakendi infoleht III lisas.
English: On 23 February 2007, Denmark presented to the EMEA a referral under Article 30 of Directive 2001/83/EC, as amended, in order to harmonise the nationally authorised summaries of product characteristics, package leaflet and labelling of the medicinal product Cozaar Comp. and associated names.
Estonian: 23. veebruaril 2007 esitas Taani Euroopa Ravimiametile muudetud direktiivi 2001/83/EÜ artikli 30 alusel esildise, et ühtlustada ravimi Cozaar Comp ja sarnaste nimetuste ravimi omaduste kokkuvõtted, pakendi infolehed ja märgistus.
English: The losartan/hydrochlorothiazide combination is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled on losartan or hydrochlorothiazide.
Estonian: Losartaani ja hüdroklorotiasiidi kombinatsioon on näidustatud hüpertensiooni raviks patsientidel, kellel kas ainult losartaani või hüdroklorotiasiidiga ei saavutata küllaldast vererõhu langust.
English: The CHMP gave a positive opinion on 24 April 2008 recommending the harmonisation of the SPC, labelling and package leaflet for Cozaar Comp. and associated names.
Estonian: Inimravimikomitee esitas positiivse arvamuse 24. aprillil 2008, soovitades ühtlustada ravimi Cozaar Comp ja sarnaste nimetuste ravimi omaduste kokkuvõtted, märgistused ja pakendi infolehed.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 30 REFERRAL FOR Cozaar Comp and associated names International Non-Proprietary Name (INN): losartan + hydrochlorothiazide
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): losartaan + hüdroklorotiasiid
English: What is Levact?
Estonian: Mis on Levact?
English: The European Commission issued a decision on 7 July 2010.
Estonian: Euroopa Komisjon tegi otsuse 7. juulil 2010.
English: Harald Enzmann (Germany)
Estonian: Harald Enzmann (Saksamaa)
English: Jean-François Baurain (Belgium)
Estonian: Jean-François Baurain (Belgia)
English: Bendamustine has been used in anticancer medicines in Germany since the early 1970s.
Estonian: Bendamustiini on kasutatud vähiravimites Saksamaal 1970ndate aastate algusest.
English: Why was Levact reviewed?
Estonian: Miks ravimi Levact taotlus uuesti üle vaadati?
English: It is used to treat the following types of cancer:
Estonian: Seda kasutatakse järgmiste vähivormide raviks:
English: The Committee therefore recommended that Levact be granted marketing authorisation in Germany and all concerned Member States for all the indications that were applied for.
Estonian: Seetõttu soovitas komitee anda Levacti müügiloa Saksamaal ja kõikides asjaomastes liikmesriikides kõikideks taotletud näidustusteks.
English: Astellas Pharma GmbH submitted Levact to the German medicines regulatory agency for a decentralised procedure.
Estonian: Astellas Pharma GmbH esitas Levacti Saksamaa ravimiametile detsentraliseeritud menetluse läbiviimiseks.
English: As a result, the cancer cells cannot divide and the growth of tumours slows down.
Estonian: Selle tulemusena ei saa vähirakud paljuneda ning see aeglustab kasvaja kasvu.
English: The grounds for the referral were that one Member State, the United Kingdom, could not approve the indication non-Hodgkin's lymphoma, and two Member States, Belgium and France, could not approve the indication multiple myeloma because not enough data on the effectiveness of this medicine were available to support these indications.
Estonian: Esildise tegemise aluseks oli asjaolu, et üks liikmesriik, Ühendkuningriik, ei kiitnud heaks mitteHodgkini lümfoomi näidustust, ja kaks liikmesriiki, Belgia ja Prantsusmaa, ei kiitnud heaks hulgimüeloomi näidustust, sest nende näidustuste toetuseks ei olnud esitatud piisavalt andmeid ravimi efektiivsuse kohta.
English: It binds to the DNA of cells while they are reproducing, which stops cell division.
Estonian: See seondub rakkude paljunemise ajal nende DNAga, mis katkestab rakkude pooldumise.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Levact outweigh its risks, and that the marketing authorisation can be granted in Germany and in the following Member States: Austria, Belgium, Denmark, Finland, France, Ireland, Italy, Luxembourg, Norway, Poland, Spain and the United Kingdom.
Estonian: Inimravimite komitee otsustas, et ravimi Levact kasulikkus on suurem kui sellega kaasnevad riskid ning ravimi müügiloa võib anda Saksamaal ja järgmistes liikmesriikides: Austria, Belgia, Hispaania, Iirimaa, Itaalia, Luksemburg, Norra, Poola, Prantsusmaa, Soome, Taani ja Ühendkuningriik.
English: Based on the evaluation of these data and the scientific discussion within the Committee, the CHMP concluded that the benefits of Levact outweigh its risks for the two indications for which objections were raised.
Estonian: Tuginedes nende andmete hindamisele ja komiteesisesele teaduslikule arutelule, jõudis inimravimite komitee järeldusele, et nende kahe näidustuse osas, mille suhtes esitati vastuväited, on Levacti kasulikkus suurem kui sellega kaasnevad riskid.
English: 7 July 2010
Estonian: 7. juuli 2010
English: 22 October 2009
Estonian: 22. oktoober 2009
English: However, the Member States were not able to reach an agreement and the German medicines regulatory agency referred the matter to the CHMP for arbitration on 2 October 2009.
Estonian: Liikmesriigid ei jõudnud kokkuleppele ja Saksamaa ravimiamet tegi 2. oktoobril 2009 inimravimite komiteele esildise vahekohtumenetluse alustamiseks.
English: Levact is also known as Ribomustin.
Estonian: Levacti tuntakse ka Ribomustini nime all.
English: 18 March 2010
Estonian: 18. märts 2010
English: 14 January 2010 and 17 February 2010
Estonian: 14. jaanuar 2010 ja 17. veebruar 2010
English: The European Medicines Agency has completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Levact and associated names.
Estonian: Euroopa Ravimiamet on lõpetanud vahekohtumenetluse, mis algatati pärast seda, kui Euroopa Liidu liikmesriigid ei jõudnud kokkuleppele ravimi Levact ja sarnaste nimetuste heakskiitmises.
English: This is a procedure where one Member State (the ‘reference Member State', in this instance Germany) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned Member States', in this instance Belgium, Denmark, Finland, France, Ireland, Italy, Luxembourg, Norway, Poland, Spain and the United Kingdom).
Estonian: Saksamaa) hindab ravimit, et otsustada, kas anda ravimile müügiluba, mis kehtib selles riigis ja ka teistes liikmesriikides (asjaomased liikmesriigid, käesoleval juhul Austria, Belgia, Hispaania, Iirimaa, Itaalia, Luksemburg, Norra, Poola, Prantsusmaa, Soome, Taani ja Ühendkuningriik).
English: Questions and answers on Levact and associated names (bendamustine hydrochloride, 2.5 mg/ml, powder for concentrate for solution for infusion) EMA/CHMP/735863/2009
Estonian: Teave ravimi Levact ja sarnaste nimetuste kohta (bendamustiin hüdrokloriid, 2,5 mg/ml, infusioonilahuse kontsentraadi pulber) EMA/CHMP/735863/2009
English: The CHMP assessed the two clinical studies presented by the company to support the multiple myeloma and non-Hodgkin's lymphoma indications.
Estonian: Inimravimite komitee hindas kaht kliinilist uuringut, mille ettevõte esitas hulgimüeloomi ja mitteHodgkini lümfoomi näidustuse toetuseks.
English: Levact is an anticancer medicine.
Estonian: Levact on vähiravim.
English: Co-Rapporteur:
Estonian: Kaashindaja:
English: Questions and answers on Levact and associated names (bendamustine hydrochloride, 2.5 mg/ml, powder for concentrate for solution for infusion)
Estonian: Teave ravimi Levact ja sarnaste nimetuste kohta (bendamustiin hüdrokloriid, 2,5 mg/ml, infusioonilahuse kontsentraadi pulber)
English: • multiple myeloma (a cancer of the bone marrow) in combination with prednisone in patients older than 65 years who are not eligible for stem-cell transplantation and cannot be treated with thalidomide or bortezomib (other anticancer medicines).
Estonian: • hulgimüeloom (luuüdi vähk), kombinatsioonis prednisooniga, üle 65-aastastel patsientidel, kellele ei saa teha tüvirakkude siirdamist ning keda ei saa ravida talidomiidi või bortesomiibiga (samuti vähiravimid).
English: The active substance in Levact, bendamustine hydrochloride, belongs to a group of anticancer medicines called ‘alkylating agents'.
Estonian: Levacti toimeaine bendamustiin hüdrokloriid kuulub alküleerivateks aineteks nimetatavate vähiravimite rühma.
English: Referral start date:
Estonian: Esildise tegemise kuupäev:
English: • non-Hodgkin's lymphoma (a cancer of the lymph tissue, part of the immune system) in patients whose cancer got worse during or following treatment containing rituximab (another anticancer medicine);
Estonian: • mitte-Hodgkini lümfoom (lümfikoe - immuunsüsteemi osa - vähk) patsientidel, kelle haigus progresseerus rituksimabi (samuti vähiravim) sisaldava ravi ajal või pärast seda;
English: • chronic lymphocytic leukaemia (a cancer of a type of white blood cell called lymphocytes) in patients for whom treatment with fludarabine (another anticancer medicine) is not appropriate;
Estonian: • krooniline lümfotsüütiline leukeemia (lümfotsüütide - teatud valgeliblede - vähk) patsientidel, kellele ei sobi ravi fludarabiiniga (samuti vähiravim);
English: What measures are being taken to ensure the safe and effective use of Trumenba?
Estonian: Mis meetmed võetakse, et tagada Trumenba ohutu ja efektiivne kasutamine?
English: It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use.
Estonian: Selles selgitatakse, kuidas amet hindas vaktsiini, et soovitada müügiloa andmist Euroopa Liidus ja kasutustingimusi.
English: Further planned or ongoing studies are expected to provide more information on Trumenba's effectiveness.
Estonian: Kavandatud või pooleliolevad lisauuringud annavad eeldatavalt rohkem teavet Trumenba efektiivsuse kohta.
English: The full EPAR for Trumenba can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Trumenba kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Trumenba
Estonian: Muu teave Trumenba kohta
English: Although side effects were common, they appeared to be within acceptable limits.
Estonian: Kuigi kõrvalnähte esines sagedasti, leiti need olevat talutavuse piirides.
English: Trumenba can only be obtained with a prescription and should be used according to official recommendations.
Estonian: Trumenba on retseptivaktsiin ja seda tuleb kasutada vastavalt ametlikele soovitustele.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that based on available data Trumenba's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et olemasolevate andmete põhjal on Trumenba kasulikkus suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
English: The most common side effects with Trumenba (which may affect more than 1 in 10 people) are pain, redness or swelling at the site of the injection, headache, tiredness, chills, diarrhoea, nausea (feeling sick), and muscle or joint pain.
Estonian: Trumenba kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on valu, punetus või turse süstekohal, peavalu, väsimus, külmavärinad, kõhulahtisus, iiveldus ja lihase- või liigesevalu.
English: These proteins are fixed onto a compound containing aluminium (adsorbed), which helps to stabilise them, allowing the immune system to respond to them.
Estonian: Need proteiinid kinnitatakse alumiiniumit sisaldavale ühendile (adsorbeeritakse), mis aitab neid stabiliseerida ja seeläbi stimuleerida immuunvastust.
English: Why is Trumenba approved?
Estonian: Miks Trumenba heaks kiideti?
English: Initial treatment may either involve 2 injections at least 6 months apart, or 2 injections at least 1 month apart followed by a third injection at least 4 months later.
Estonian: Esmane vaktsineerimine võib sisaldada 2 süsti, mis manustatakse vähemalt 6kuulise vahega, või 2 süsti, mis manustatakse vähemalt 1-kuulise vahega, millele järgneb vähemalt 4 kuud hiljem kolmas süst.
English: What is Trumenba and what is it used for?
Estonian: Mis on Trumenba ja milleks seda kasutatakse?
English: This is a summary of the European public assessment report (EPAR) for Trumenba.
Estonian: See on vaktsiini Trumenba Euroopa avaliku hindamisaruande kokkuvõte.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Trumenba have been included in the summary of product characteristics and the package leaflet.
Estonian: Trumenba ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Trumenba meningococcal group B vaccine (recombinant, adsorbed)
Estonian: B-grupi meningokoki vaktsiin (rekombinantne, adsorbeeritud)
English: It is available in a pre-filled syringe and is given by injection into a muscle, preferably in the shoulder.
Estonian: Seda turustatakse eeltäidetud süstlas ning manustatakse intramuskulaarse süstena, eelistatavalt õlavarrelihasesse.
English: What are the risks associated with Trumenba?
Estonian: Mis riskid Trumenbaga kaasnevad?
English: The studies also looked at response to 10 other, secondary strains of N. meningitidis group B.
Estonian: Uuringutes analüüsiti ka vastust kümnele teisele, sekundaarsele B-grupi N. meningitidise tüvele.
English: In patients at greater risk of invasive meningococcal disease, an additional booster dose may be considered later on.
Estonian: Suurema invasiivse meningokokilise haiguse riskiga patsientidel võib kaaluda hilisemat revaktsineerimist.
English: It is not intended to provide practical advice on how to use Trumenba.
Estonian: Hindamisaruandes ei anta Trumenba kasutamise praktilisi nõuandeid.
English: In the second study sufficient amounts of antibodies were produced in 79 to 90% of cases, and protective levels of antibodies against all 4 strains were seen in 85% of participants.
Estonian: Teises uuringus tekkis piisav antikehasisaldus 79-90%-l juhtudest ning 85%-l osalenutest täheldati kõigi nelja tüve vastu kaitsvat antikehade sisaldust.
English: As the protection provided seemed to decline over time, a booster dose should be considered in recipients who were thought to be at continued risk of invasive meningococcal disease.
Estonian: Et kaitsev toime tundub aja jooksul vähenevat, tuleb kaaluda selliste patsientide revaktsineerimist, kellel on jätkuv risk invasiivse meningokokilise haiguse tekkeks.
English: When the person is then exposed to the bacterium, these antibodies together with other components of the immune system will be able to kill the bacteria and help protect against the disease.
Estonian: Kui inimene puutub bakteriga kokku, hävitavad antikehad ja muud immuunsüsteemi osad bakteri ning aitavad kaitsta organismi haiguse eest.
English: Supportive studies were also carried out, which showed that 2 doses of the vaccine achieved a broadly similar antibody response to 3 doses, and that even though protective antibody levels declined over time they could be improved by an additional booster dose after both 2- and 3-dose treatments.
Estonian: Tehti ka toetavad uuringud, kust nähtus, et kaheannuselise vaktsineerimisskeemi kasutamisel oli antikehavastus üldjoontes sarnane kolmeannuselise vaktsineerimisskeemi antikehavastusega ning et isegi kui kaitsev antikehade sisaldus aja jooksul väheneb, on seda mõlema skeemi korral võimalik suurendada pärast teist või kolmandat süsti manustatava revaktsineerimisannusega.
English: Invasive disease occurs when these bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spinal cord) and septicaemia (blood infection).
Estonian: Invasiivne haigus tekib, kui bakterid levivad kogu organismis, põhjustades raskeid infektsioone, näiteks meningiiti (ajukelmepõletik) ja sepsist (nakkusveresus).
English: Antibody responses were also seen against the 10 secondary strains and confirmed the responses seen with the 4 main strains.
Estonian: Vaktsineeritutel täheldati antikehavastust ka kümnele sekundaarsele tüvele ja need kinnitasid nelja põhitüvega täheldatud antikehavastust.
English: For the full list of all side effects and restrictions with Trumenba, see the package leaflet.
Estonian: Trumenba kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: For practical information about using Trumenba, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Trumenba kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Trumenba, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Trumenbaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Antibodies were produced in sufficient quantities to provide protection against the 4 main test strains in between 80 and 90% of those in the first study, depending on the strain; 84% of those given the vaccine had protective antibodies against all 4 strains when tested.
Estonian: Piisav antikehasisaldus nelja peamise analüüsitud tüve vastu tekkis 80-90%-l esimeses uuringus osalenutest, olenevalt tüvest; 84%-l vaktsineeritutest olid analüüsi ajaks tekkinud antikehad kõigi nelja tüve vastu.
English: When a person is given the vaccine, the immune system recognises the parts of the bacterium contained in the vaccine as ‘foreign' and makes antibodies against them.
Estonian: Kui inimesele manustatakse vaktsiini, peab immuunsüsteem vaktsiinis sisalduvaid bakteriosi võõraks ja tekitab nende vastu antikehi.
English: How is Trumenba used?
Estonian: Kuidas Trumenbat kasutatakse?
English: The available data indicated that Trumenba should provide broad protection against the strains of Neisseria meningitidis group B that are currently found in Europe, whether given in a 3-dose or a 2dose schedule.
Estonian: Olemasolevad andmed näitasid, et Trumenba peaks andma tugeva kaitse Euroopas praegu leiduvate B-grupi Neisseria meningitidise tüvede vastu olenemata sellest, kas vaktsiini manustatakse kolme või kahe annusena.
English: The first study involved around 3,600 participants aged 10 to 18 years, and the second study involved around 3,300 young adults between 18 and 25 years of age; none of the participants had previously been vaccinated against N. meningitidis group B. Those taking part were given 3 doses of the vaccine and antibody response against 4 main test strains of the bacteria (the ones usually responsible for disease in Europe) was measured one month after the last injection.
Estonian: Esimene uuring hõlmas umbes 3600 10-18-aastast osalejat ning teine uuring umbes 3300 18-25-aastast noort täiskasvanut; ühtki osalenutest ei olnud varem B-grupi N. meningitidise vastu vaktsineeritud.
English: How does Trumenba work?
Estonian: Kuidas Trumenba toimib?
English: Trumenba contains two components, proteins that are found in the outer coats of Neisseria meningitidis group B bacteria.
Estonian: Trumenba sisaldab kaht proteiini, mida leidub B-grupi Neisseria meningitidise bakterite väliskestal.
English: What benefits of Trumenba have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Trumenba kasulikkus?
English: Trumenba is a vaccine used to protect individuals from 10 years old against invasive meningococcal disease caused by a group of bacteria called Neisseria meningitidis group B.
Estonian: Trumenba on vaktsiin, mida kasutatakse B-grupi Neisseria meningitidise (teatud bakterirühm) põhjustatud invasiivse meningokokilise haiguse eest kaitsmiseks alates 10. eluaastast.
English: Trumenba has been shown to trigger the production of protective levels of antibodies against Neisseria meningitidis group B in two main studies.
Estonian: Kahes põhiuuringus tõendati, et Trumenba aktiveerib B-grupi N. meningitidise vastu kaitsva antikehavastuse tekke.
English: This may take up to 60 minutes.
Estonian: Selleks võib kuluda kuni 60 minutit.
English: Participation in the registry is voluntary.
Estonian: Osalemine registris on vabatahtlik.
English: These reactions usually go away within a few days.
Estonian: Nimetatud reaktsioonid mööduvad tavaliselt mõne päevaga.